Daniel Faga Sells 9,202 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 9,202 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $415,102.22. Following the transaction, the chief executive officer owned 466,787 shares in the company, valued at $21,056,761.57. The trade was a 1.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Daniel Faga also recently made the following trade(s):

• On Thursday, January 8th, Daniel Faga sold 14,281 shares of AnaptysBio stock. The stock was sold at an average price of $44.71, for a total value of $638,503.51.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Trading Up 2.0%

Shares of AnaptysBio stock opened at $44.67 on Friday. The stock’s fifty day moving average price is $42.62 and its 200-day moving average price is $31.46. The firm has a market cap of $1.24 billion, a P/E ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $52.47.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. Analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has initiated a share buyback plan on Friday, November 21st that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

Institutional Investors Weigh In On AnaptysBio

Large investors have recently made changes to their positions in the stock. Larson Financial Group LLC increased its position in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares during the period. Rhumbline Advisers grew its stake in AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after purchasing an additional 826 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the period. Corton Capital Inc. increased its holdings in shares of AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 1,305 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ANAB. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. HC Wainwright cut their target price on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Wells Fargo & Company raised their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research report on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.